Buy Us a Cup of Coffee

Frontage Completes Expansion of its Bioanalytical Laboratories in Exton

Frontage Completes Expansion of Bioanalytical Capacity and Capabilities to Support Biologic and Small Molecule Drug DevelopmentRibbon cutting ceremony attended by leadership team including Dr. Song Li, CEO; Dr. John Lin, EVP Bioanalytical and Biologics Services; Dr Zeke Li, SVP; Sridhar Krishnan, SVP Global Operations

EXTON, PA — Frontage Holdings Corporation, a contract research organization (“CRO”) providing integrated, science-driven, product development services, recently announced the expansion of its bioanalytical laboratories in Exton, PA, through its wholly-owned subsidiary, Frontage Laboratories, Inc.

This includes an additional 10,000 square feet of laboratory space which further enhances bioanalytical capabilities in biologics and small molecule drug development, biomarkers, cell and gene therapy, and high-throughput clinical sample management. The expansion brings the total laboratory space in Frontage’s Exton site to 80,000 square feet.

The expansion further demonstrates the Group’s commitment to supporting clients’ drug development programs for biologics and small molecules, including cell and gene therapies, as well as biomarker testing.

In addition to sample management and increased laboratory space, we have also enhanced our instrumentation, systems, robotics automation, software and personnel capacity. A center of excellence supporting cell and gene therapy has been established which includes dedicated laboratories in DNA/RNA sample preparation, PCR, flow cytometry, and cell culture.

The expansion provides greater biomarker, PK, and immunogenicity bioanalytical capacity to support large Clinical Phase II-IV studies.

According to Dr. John Lin, PhD, EVP of Frontage’s Global Bioanalytical Services, “The expansion provides our clients with heightened biomarker and biologic services in a state-of-the-art facility to facilitate drug discovery and development.  It enables Frontage to provide the enhanced capability and capacity for the bioanalytical support of the gene and cell therapies and late phase clinical studies.”

In September 2019, the facility in Shanghai added an additional 42,000 square feet dedicated to the bioanalytical effort and sample management of small molecule programs. Overall, Frontage Laboratories has added 52,000 square feet globally to support the bioanalytical business in less than 4 months.

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.

Buy Us a Cup of Coffee